Kamada Ltd. - Ordinary Shares (KMDA): Price and Financial Metrics


Kamada Ltd. - Ordinary Shares (KMDA)

Today's Latest Price: $8.33 USD

0.03 (0.36%)

Updated Oct 22 4:00pm

Add KMDA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

KMDA Stock Summary

  • With a year-over-year growth in debt of 2,956.91%, Kamada Ltd's debt growth rate surpasses 99.05% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Kamada Ltd is reporting a growth rate of -325.17%; that's higher than only 5.74% of US stocks.
  • As for revenue growth, note that KMDA's revenue has grown 81.94% over the past 12 months; that beats the revenue growth of 93.58% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Kamada Ltd, a group of peers worth examining would be UTSI, OIIM, AWRE, MOSY, and RIGL.
  • Visit KMDA's SEC page to see the company's official filings. To visit the company's web site, go to www.kamada.com.

KMDA Stock Price Chart Interactive Chart >

Price chart for KMDA

KMDA Price/Volume Stats

Current price $8.33 52-week high $13.33
Prev. close $8.30 52-week low $4.40
Day low $8.13 Volume 62,900
Day high $8.38 Avg. volume 227,619
50-day MA $8.99 Dividend yield N/A
200-day MA $7.64 Market Cap 370.85M

Kamada Ltd. - Ordinary Shares (KMDA) Company Bio


Kamada Ltd. develops, produces, and markets specialty plasma-derived protein therapeutics. It operates through two segments, Proprietary Products and Distribution. The company was founded in 1990 and is based in Ness Ziona, Israel.

KMDA Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$8.33$1852.34 21795%

Below please find a table outlining a discounted cash flow forecast for KMDA, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Kamada Ltd ranked in the 98th percentile in terms of potential gain offered. Our DCF analysis implies the stock could yield a return of 21902.67% if fairly valued; such returns are always unlikely, though, so further investigation is likely warranted. In terms of the factors that were most noteworthy in this DCF analysis for KMDA, they are:

  • As a business, KMDA is generating more cash flow than merely 24.26% of positive cash flow stocks in the Healthcare.
  • The business' balance sheet reveals debt to be 2% of the company's capital (with equity being the remaining amount). Approximately merely 7.56% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
  • KMDA's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 50.49% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%21366%
1%21581%
2%21795%
3%22010%
4%22225%
5%22439%

Want more companies with a valuation profile/forecast similar to that of Kamada Ltd? See VRTX, ASNB, GEN, AMEH, and AMRX.


KMDA Latest News Stream


Event/Time News Detail
Loading, please wait...

KMDA Latest Social Stream


Loading social stream, please wait...

View Full KMDA Social Stream

Latest KMDA News From Around the Web

Below are the latest news stories about Kamada Ltd that investors may wish to consider to help them evaluate KMDA as an investment opportunity.

FDA to fast-track COVID-19 vaccine - Financial Times

The chief of the FDA is willing to bypass the full federal approval process in order to make a COVID-19 vaccine available as soon as possible.However, the move is not intended to please President Donald Trump, said FDA Commissioner Stephen Hahn. An emergency authorization could be appropriate before Phase Three...

Seeking Alpha | August 31, 2020

FDA to Fast Track COVID-19 vaccine - Financial Times

The chief of the FDA is willing to bypass the full federal approval process in order to make a COVID-19 vaccine available as soon as possible.However, the move is not intended to please President Donald Trump, said FDA Commissioner Stephen Hahn. An emergency authorization could be appropriate before Phase Three...

Seeking Alpha | August 31, 2020

The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDA...

Benzinga | August 25, 2020

Thinking about buying stock in Kamada Ltd, TFF Pharmaceuticals, Hexo Corp, AMC Entertainment, or Delta Air Lines?

NEW YORK, Aug. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KMDA, TFFP, HEXO, AMC, and DAL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….

PR Newswire | August 14, 2020

Kamada Reports Second Quarter and First Six Months of 2020 Financial Results, Recent Corporate Achievements and Strong Cash Position

Second Quarter Revenues were $33.1 million, Compared to $35.3 million in 2019, First Half 2020 Revenues were $66.4 million, up 7% from 2019 Net Income for …

Benzinga | August 12, 2020

Read More 'KMDA' Stories Here

KMDA Price Returns

1-mo 0.73%
3-mo -4.03%
6-mo 12.57%
1-year 62.70%
3-year 63.33%
5-year 108.25%
YTD 21.96%
2019 36.60%
2018 5.26%
2017 -12.84%
2016 31.33%
2015 9.21%

Continue Researching KMDA

Want to see what other sources are saying about Kamada Ltd's financials and stock price? Try the links below:

Kamada Ltd (KMDA) Stock Price | Nasdaq
Kamada Ltd (KMDA) Stock Quote, History and News - Yahoo Finance
Kamada Ltd (KMDA) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6947 seconds.